Create
Log in
Sign up
Golden has been acquired by ComplyAdvantage.
Read about it here ⟶
US Patent 10800786 Bicyclic compounds as ATX inhibitors
Overview
Structured Data
Issues
Contributors
Activity
All edits
Edits on 14 Jun, 2023
"update inverses"
Golden AI
edited on 14 Jun, 2023
Edits made to:
Infobox
(
+1
properties)
Infobox
Patent Citations Received
US Patent 11673888 Bicyclic compounds as ATX inhibitors
0
Edits on 25 May, 2023
"Remove website redirecting to Patent Public Search front page"
Golden AI
edited on 25 May, 2023
Edits made to:
Infobox
(
-1
properties)
Infobox
Official Website
https://pdfpiw.uspto.gov/.piw?Docid=10800786
Edits on 29 Apr, 2023
"update citations for inverse infoboxes"
Golden AI
edited on 29 Apr, 2023
Infobox
Patent Citations Received
US Patent 11059794 Heterocyclic compounds useful as dual ATX/CA inhibitors
0
Edits on 27 Apr, 2023
"update citations for inverse infoboxes"
Golden AI
edited on 27 Apr, 2023
Infobox
Patent Citations
US Patent 10647719 Bicyclic compounds as dual ATX/CA inhibitors
0
Edits on 7 Apr, 2023
"update citations for inverse infoboxes"
Golden AI
edited on 7 Apr, 2023
Infobox
Patent Citations
US Patent 10633384 Diazaspirocycloalkane and azaspirocycloalkane
0
Edits on 22 Mar, 2023
"update citations for inverse infoboxes"
Golden AI
edited on 22 Mar, 2023
Infobox
Patent Citations
US Patent 10208052 Compositions for activating pyruvate kinase
0
Edits on 27 Sep, 2022
"update citations for inverse infoboxes"
Golden AI
edited on 27 Sep, 2022
Infobox
Patent Citations
US Patent 10647719 Bicyclic compounds as dual ATX/CA inhibitors
0
"update citations for inverse infoboxes"
Golden AI
edited on 27 Sep, 2022
Infobox
Patent Citations
US Patent 10633384 Diazaspirocycloalkane and azaspirocycloalkane
0
Edits on 25 Sep, 2022
"update citations for inverse infoboxes"
Golden AI
edited on 25 Sep, 2022
Infobox
Patent Citations Received
US Patent 11059794 Heterocyclic compounds useful as dual ATX/CA inhibitors
0
"update citations for inverse infoboxes"
Golden AI
edited on 25 Sep, 2022
Infobox
Patent Citations
US Patent 10654857 Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors
0
Edits on 17 Jun, 2022
"Entity importer update"
Golden AI
edited on 17 Jun, 2022
Edits made to:
Infobox
(
+1
properties)
Infobox
Website URL
https://pdfpiw.uspto.gov/.piw?Docid=10800786
Edits on 9 Jun, 2022
"update inverses"
Golden AI
edited on 9 Jun, 2022
Edits made to:
Infobox
(
+1
properties)
Infobox
Patent citations received
US Patent 11352330 Phenoxymethyl derivatives
Edits on 12 Feb, 2022
"update inverses"
Golden AI
edited on 12 Feb, 2022
Edits made to:
Infobox
(
+1
properties)
Infobox
Patent citations received
US Patent 11059794 Heterocyclic compounds useful as dual ATX/CA inhibitors
Edits on 7 Feb, 2022
"Created via: Entity Importer"
Golden AI
created this topic on 7 Feb, 2022
Edits made to:
Infobox
(
+12
properties)
US Patent 10800786 Bicyclic compounds as ATX inhibitors
Infobox
Is a
Patent
Patent jurisdiction
United States Patent and Trademark Office
Patent number
10800786
Date of patent
October 13, 2020
Patent application number
16380909
Date Filed
April 10, 2019
Patent citations
US Patent 10208052 Compositions for activating pyruvate kinase
US Patent 10633384 Diazaspirocycloalkane and azaspirocycloalkane
US Patent 10640472 Phenoxymethyl derivatives
US Patent 10647719 Bicyclic compounds as dual ATX/CA inhibitors
US Patent 10654857 Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors
Patent primary examiner
Alicia L Otton
Find more entities like US Patent 10800786 Bicyclic compounds as ATX inhibitors
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Company
Home
Press & Media
Blog
Careers
WE'RE HIRING
Products
Knowledge Graph
Query Tool
Data Requests
Knowledge Storage
API
Pricing
Enterprise
ChatGPT Plugin
Legal
Terms of Service
Enterprise Terms of Service
Privacy Policy
Help
Help center
API Documentation
Contact Us
By using this site, you agree to our
Terms of Service
.
SUBSCRIBE